miRNA-221: A Potential Biomarker of Progressive Liver Injury in Chronic Liver Disease (CLD) due to Hepatitis B Virus (HBV) and Nonalcoholic Fatty Liver Disease (NAFLD)
Conclusion: miRNA-221 may be used as a potential plasma biomarker for early prediction of fibrosis progression in CLD patients.
Saved in:
Main Authors: | Parthana Rani Sutradhar, Nahida Sultana, Afzalun Nessa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | International Journal of Hepatology |
Online Access: | http://dx.doi.org/10.1155/2024/4221368 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease
by: Sumitro Kosasih, et al.
Published: (2018-01-01) -
Update on Ppar𝜸 and Nonalcoholic Fatty Liver Disease
by: Gene P. Ables
Published: (2012-01-01) -
Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
by: Roberto Martínez-Beamonte, et al.
Published: (2020-01-01) -
Nonalcoholic Fatty Liver Disease in Patients Investigated for Elevated Liver Enzymes
by: Krikor Kichian, et al.
Published: (2003-01-01) -
Oxidative stress and inflammation in hemodialysis: a comparison of patients with or without advanced nonalcoholic fatty liver disease (NAFLD)
by: Vanja Kalacun, et al.
Published: (2025-12-01)